butyrylfentanyl | 1169-70-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: butyrylfentanyl
• 英文别名: butyrfentanyl；Butanamide, N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-；N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]butanamide
• CAS: 1169-70-6
• 化学式: C₂₃H₃₀N₂O
• 分子量: 350.504
• InChiKey: QQOMYEQLWQJRKK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

ADMET

代谢

丁酰芬太尼可以通过CYP3A4和CYP2D6去烷基化成为诺丁酰芬太尼，通过CYP3A4羟基化成为(ω-1)-羟基-丁酰芬太尼，4'-位羟基化成为4'-羟基-丁酰芬太尼，通过CYP2D6或CYP3A4羟基化成为ω-羟基-丁酰芬太尼，或者通过CYP3A4羟基化成为β-羟基-丁酰芬太尼。ω-羟基-丁酰芬太尼进一步代谢成为ω-羧基-丁酰芬太尼，而4'-羟基-丁酰芬太尼进一步代谢成为4'-羟基-3'-甲氧基-丁酰芬太尼。这些代谢物中的许多可能会与葡萄糖醛酸或硫酸进一步发生共轭反应。

Butyrfentanyl can be N-dealkylated to nor-butyrfentanyl by CYP3A4 and CYP2D6, hydroxylated to (ω-1)-hydroxy-butyrfentanyl by CYP3A4, 4'-hydroxylated to 4'-hydroxy-butyrfentanyl, hydroxylated to ω-hydroxy-butyrfentanyl bye CYP2D6 or CYP3A4, or hydroxylated to β-hydroxy-butyrfentanyl by CYP3A4. ω-hydroxy-butyrfentanyl is further metabolized to ω-carboxy-butyrfentanyl while 4'-hydroxy-butyrfentanyl is further metabolized to 4'-hydroxy-3'-methoxy-butyrfentanyl. Many of these metabolites may undergo further conjugation reactions with glucuronic acid or sulfate.

来源:DrugBank

毒理性

• 蛋白质结合

丁酸芬太尼的蛋白质结合研究尚未进行，但由于其与芬太尼的结构相似性，它很可能在循环中高度结合血清白蛋白和α-1-酸性糖蛋白。

Protein binding studies for butyrfentanyl have not been performed but due to its structural similarity with fentanyl it is likely highly bound to serum albumin and alpha-1-acid glycoprotein in circulation.

来源:DrugBank

吸收、分配和排泄

• 吸收

丁酸芬太尼的吸收数据不容易获得。

Data for the absorption of butyrfentanyl are not readily available.

来源:DrugBank

吸收、分配和排泄

• 消除途径

丁酸芬太尼的消除途径在文献中尚未被很好地描述，但大多数阿片类药物主要在尿液中消除。

The route of elimination of butyrfentanyl has not been well described in the literature but most opioids are mainly eliminated in the urine.

来源:DrugBank

吸收、分配和排泄

• 分布容积

丁酸芬太尼的分布容积数据不易获得。

Data for the volume of distribution of butyrfentanyl are not readily available.

来源:DrugBank

吸收、分配和排泄

• 清除

丁酸芬太尼的清除数据不容易获得。

Data for the clearance of butyrfentanyl are not readily available.

来源:DrugBank

反应信息

• 作为反应物：
  描述：

  butyrylfentanyl 在 盐酸 作用下， 以 甲醇 、 水 为溶剂， 生成 Butyrfentanyl hydrochloride
  参考文献：
  名称：

  Metabolism of Butyrylfentanyl in Fresh Human Hepatocytes: Chemical Synthesis of Authentic Metabolite Standards for Definitive Identification

  摘要：

  使用从肝人源化小鼠模型中分离的新鲜人肝细胞，研究了一种新型设计药物丁酰芬太尼的代谢情况。在与人肝细胞共培养的介质中，鉴定出了丁酰芬太尼的脱芬太尼代谢物（去甲丁酰芬太尼）、ω-羟基丁酰芬太尼、(ω-1)-羟基丁酰芬太尼、4′-羟基丁酰芬太尼、β-羟基丁酰芬太尼、4′-羟基-3′-甲氧基丁酰芬太尼和ω-羧基芬太尼作为其代谢物。每个代谢物通过与标准品的分析数据比较得到确切鉴定。主要代谢物去甲丁酰芬太尼的量在48小时达到了初始丁酰芬太尼量的37%。由丁酰芬太尼的N-丁酰基团羟化形成的ω-羟基丁酰芬太尼和(ω-1)-羟基丁酰芬太尼分别为第二和第三大代谢物。大多数4′-羟基丁酰芬太尼和4′-羟基-3′-甲氧基丁酰芬太尼被认为是共轭物。使用人肝微粒体和各种抗CYP抗体对丁酰芬太尼进行CYP反应表型分析显示，CYP3A4参与了去甲丁酰芬太尼、(ω-1)-羟基丁酰芬太尼和β-羟基丁酰芬太尼的形成。相比之下，CYP2D6参与了ω-羟基丁酰芬太尼的形成。

  DOI：

  10.1248/bpb.b18-00765
• 作为产物：
  描述：

  N-(1-phenethylpiperidin-4-ylidene)aniline 在 sodium tetrahydroborate 作用下， 生成 butyrylfentanyl
  参考文献：
  名称：

  Evaluation of Agonistic Activity of Fluorinated and Nonfluorinated Fentanyl Analogs on μ-Opioid Receptor Using a Cell-Based Assay System

  摘要：

  使用基于细胞的检测系统研究了含氟和不含氟的芬太尼类似物在μ-阿片受体上的拮抗活性。根据活性，芬太尼类似物的排名如下：芬太尼 > 异丁酰芬太尼 ≈ 丁酰芬太尼 ≈ 甲氧基乙酰芬太尼 > 乙酰芬太尼。然而，在N-苯环上含氟的芬太尼类似物中，2-氟类似物显示出最强活性，而3-氟类似物显示出最弱活性。这些结果表明，2-氟化的芬太尼类似物更可能导致中毒。

  DOI：

  10.1248/bpb.b20-00780

文献信息

• Carbon-13 nuclear magnetic resonance spectra of fentanyl analogs
  作者：G. A. Brine、K. G. Boldt、P.-T. Huang、D. K. Sawyer、F. I. Carroll

  DOI：10.1002/jhet.5570260329

  日期：1989.5

  Natural abundance carbon-13 chemical shifts are reported for the hydrochloride salts of fentanyl (1a) and fifteen analogs. The signals are assigned on the basis of chemical shift theory, SFORD multiplicities, signal intensities, comparisons with model compounds, and thiophene carbon-proton coupling constants. In addition to its forensic value, the data suggest that the solution conformations of the

  据报道芬太尼（1a）和十五个类似物的盐酸盐的自然丰度碳13化学位移。信号是根据化学位移理论，SFORD多重性，信号强度，与模型化合物的比较以及噻吩碳-质子耦合常数进行分配的。除了其法医价值外，数据还表明类似物的溶液构象与盐酸芬太尼相似。
• [EN] OPIOID HAPTENS, CONJUGATES, VACCINES, AND METHODS OF GENERATING ANTIBODIES<br/>[FR] HAPTÈNES OPIOÏDES, CONJUGUÉS OPIOÏDES, VACCINS OPIOÏDES ET PROCÉDÉS DE GÉNÉRATION D'ANTICORPS
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2020018596A1

  公开（公告）日：2020-01-23

  The disclosure provides, inter alia, opioid haptens, opioid hapten conjugates, opioid vaccines, methods of treating or preventing opioid use disorder, methods of treating opioid overdose, and methods of generating and/or isolating antibodies selective for opioids.

  该披露提供了阿片样半抗原、阿片样半抗原结合物、阿片样疫苗、治疗或预防阿片类药物使用障碍的方法、治疗阿片类药物过量的方法，以及产生和/或分离选择性针对阿片类药物的抗体的方法。
• NASAL DRUG PRODUCTS AND METHODS OF THEIR USE
  申请人：Adapt Pharma Limited

  公开号：US20170071851A1

  公开（公告）日：2017-03-16

  Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided. Methods of treating opioid overdose or its symptoms with the inventive drug products are also provided.
• FENTANYL ANALOGUE DETECTION METHODS AND KITS THEREOF
  申请人：Veriteque USA, Inc.

  公开号：US20220390439A1

  公开（公告）日：2022-12-08

  A portable detection kit for identifying the presence of narcotic compounds (NCs) includes at least one chemical dye, a catalytic reagent, at least one solvent, and a least one surfactant. The at least one dry chemical dye is configured to undergo physic-chemical interaction with at least one predetermined NC to produce a color visible change. The at least one predetermined NC is selected from the group consisting of fentanyl analogues (FAs) and narcotics containing nitrogen heterocyclic moiety.
• Metabolism of Butyrylfentanyl in Fresh Human Hepatocytes: Chemical Synthesis of Authentic Metabolite Standards for Definitive Identification
  作者：Tatsuyuki Kanamori、Yuko Togawa Iwata、Hiroki Segawa、Tadashi Yamamuro、Kenji Kuwayama、Kenji Tsujikawa、Hiroyuki Inoue

  DOI：10.1248/bpb.b18-00765

  日期：2019.4.1

  The metabolism of butyrylfentanyl, a new designer drug, was investigated using fresh human hepatocytes isolated from a liver-humanized mouse model. In the culture medium of hepatocytes incubated with butyrylfentanyl, the desphenethylated metabolite (nor-butyrylfentanyl), ω-hydroxy-butyrylfentanyl, (ω-1)-hydroxy-butyrylfentanyl, 4′-hydroxy-butyrylfentanyl, β-hydroxy-butyrylfentanyl, 4′-hydroxy-3′-methoxy-butyrylfentanyl, and ω-carboxy-fentanyl were identified as the metabolites of butyrylfentanyl. Each metabolite was definitively identified by comparing the analytical data with those of authentic standards. The amount of the main metabolite, nor-butyrylfentanyl, reached 37% of the initial amount of butyrylfentanyl at 48 h. ω-Hydroxy-butyrylfentanyl and (ω-1)-hydroxy-butyrylfentanyl, formed by hydroxylation at the N-butyryl group of butyrylfentanyl, were the second and third largest metabolites, respectively. The majority of 4′-hydroxy-butyrylfentanyl and 4′-hydroxy-3′-methoxy-butyrylfentanyl was considered to be conjugated. CYP reaction phenotyping for butyrylfentanyl using human liver microsomes and various anti-CYP antibodies revealed that CYP3A4 was involved in the formation of nor-butyrylfentanyl, (ω-1)-hydroxy-butyrylfentanyl, and β-hydroxy-butyrylfentanyl. In contrast, CYP2D6 was involved in the formation of ω-hydroxy-butyrylfentanyl.

  使用从肝人源化小鼠模型中分离的新鲜人肝细胞，研究了一种新型设计药物丁酰芬太尼的代谢情况。在与人肝细胞共培养的介质中，鉴定出了丁酰芬太尼的脱芬太尼代谢物（去甲丁酰芬太尼）、ω-羟基丁酰芬太尼、(ω-1)-羟基丁酰芬太尼、4′-羟基丁酰芬太尼、β-羟基丁酰芬太尼、4′-羟基-3′-甲氧基丁酰芬太尼和ω-羧基芬太尼作为其代谢物。每个代谢物通过与标准品的分析数据比较得到确切鉴定。主要代谢物去甲丁酰芬太尼的量在48小时达到了初始丁酰芬太尼量的37%。由丁酰芬太尼的N-丁酰基团羟化形成的ω-羟基丁酰芬太尼和(ω-1)-羟基丁酰芬太尼分别为第二和第三大代谢物。大多数4′-羟基丁酰芬太尼和4′-羟基-3′-甲氧基丁酰芬太尼被认为是共轭物。使用人肝微粒体和各种抗CYP抗体对丁酰芬太尼进行CYP反应表型分析显示，CYP3A4参与了去甲丁酰芬太尼、(ω-1)-羟基丁酰芬太尼和β-羟基丁酰芬太尼的形成。相比之下，CYP2D6参与了ω-羟基丁酰芬太尼的形成。